Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
Nummular eczema (NE) is an idiopathic chronic inflammatory skin disease that occurs
throughout all life periods. Diagnosis is made primarily clinically in correlation with
histological findings. Treatment of NE is difficult. Standard treatment consists of the use
of emollients, topical as well as systemic corticosteroids and phototherapy. Nevertheless,
remission is hard to achieve and relapse occurs often. Patients usually suffer from severe
pruritus and reduced quality of life. Therefore, new therapeutic strategies are urgently
needed.
Dupilumab (Dupixent®), a monoclonal antibody inhibiting the IL-4 and IL-13 pathway by
targeting the IL-4-receptor, has been approved for the treatment of moderate-to-severe atopic
dermatitis (AD). Since there is an overlap between AD and NE with both being caused by
impaired epidermal barrier, broad immune-mediated inflammation and microbial skin
colonization, using Dupilumab in NE seems to be promising.